Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17902791 | 0.95 | AAK1 (0.36) | AAK1 | |
| SCHEMBL21064760 | 0.91 | AAK1 (0.36) | AAK1 | |
| SCHEMBL16256930 | 0.87 | AAK1 (0.35) | AAK1 | |
| SCHEMBL894455 | 0.86 | AAK1 (0.35) | AAK1 | |
| SCHEMBL17902797 | 0.85 | AAK1 (0.34) | AAK1 | |
| SCHEMBL895372 | 0.84 | AAK1 (0.34) | AAK1 | |
| SCHEMBL895099 | 0.84 | AAK1 (0.36) | AAK1 | |
| SCHEMBL895097 | 0.84 | AAK1 (0.36) | AAK1 | |
| SCHEMBL18079696 | 0.83 | AAK1 (0.33) | AAK1 | |
| SCHEMBL17902793 | 0.81 | CA12 (0.38) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240777-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-07-24 | — | — | EP | disclosed |
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | ONCO ARENDI THERAPEUTICS S.A. (PL) | 2019-06-25 | — | — | US | disclosed |
| WO-2016108707-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, PRMT1 | AAK1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.